Literature DB >> 21768942

Two-year Experience with Buprenorphine-naloxone (Suboxone) for Maintenance Treatment of Opioid Dependence Within a Private Practice Setting.

James W Finch1, Jonathan B Kamien, Leslie Amass.   

Abstract

Office-based buprenorphine-naloxone (Suboxone) treatment in the United States has significantly improved access to safe and effective opioid-dependence therapy. Little data from physicians' experiences prescribing Suboxone in private offices have been available. This retrospective chart review describes a family practitioner's first 2 years of clinical experience prescribing Suboxone for opioid dependence to 71 patients in a private office. After directly observed rapid office dose induction, Suboxone prescriptions were given monthly after evidence of continued stability. Urine was screened regularly and patients were referred for counseling and other ancillary services. Patients averaged 32 years old, 4.3 years of opioid dependence, and were primarily white (93%) and employed (70%). Fifty-two percent used heroin primarily (most by injection), and 70% had no agonist substitution therapy history. Almost half (47%) paid for their own treatment. Compliance during dose induction was excellent. Suboxone maintenance doses averaged 10 (range, 2-24) mg per day. More than 80% of urine samples were opioid-negative after Suboxone treatment began, although urinalysis did not always include a test for oxycodone. Seventy-five percent had successful outcomes by remaining in Suboxone treatment (43%), tapering successfully (21%), transferring to methadone maintenance (7%), or inpatient treatment (4%). Fifty-eight percent reported receiving counseling. Almost all (85%) paid their fees on time. There were no safety, medication abuse, or diversion issues detected. Overall, office-based Suboxone therapy was easily implemented and the physician considered the experience excellent. Suboxone maintenance was associated with good treatment retention and significantly reduced opioid use, and it is helping to reach patients, including injection drug users, without histories of agonist substitution therapy.

Entities:  

Year:  2007        PMID: 21768942     DOI: 10.1097/ADM.0b013e31809b5df2

Source DB:  PubMed          Journal:  J Addict Med        ISSN: 1932-0620            Impact factor:   3.702


  17 in total

1.  Comparing buprenorphine induction experience with heroin and prescription opioid users.

Authors:  Suzanne Nielsen; Maureen Hillhouse; Larissa Mooney; Jacqueline Fahey; Walter Ling
Journal:  J Subst Abuse Treat       Date:  2012-02-01

2.  Linkage to Primary Care for Persons First Receiving Injectable Naltrexone During Inpatient Opioid Detoxification.

Authors:  Michael D Stein; Megan M Risi; Genie L Bailey; Bradley J Anderson
Journal:  J Subst Abuse Treat       Date:  2016-02-23

3.  Antidepressant treatment does not improve buprenorphine retention among opioid-dependent persons.

Authors:  Michael D Stein; Debra S Herman; Malyna Kettavong; Patricia A Cioe; Peter D Friedmann; Tahir Tellioglu; Bradley J Anderson
Journal:  J Subst Abuse Treat       Date:  2010-07-03

Review 4.  The Role of Behavioral Interventions in Buprenorphine Maintenance Treatment: A Review.

Authors:  Kathleen M Carroll; Roger D Weiss
Journal:  Am J Psychiatry       Date:  2016-12-16       Impact factor: 18.112

Review 5.  The Clinical Applications of Extended-Release Abuse-Deterrent Opioids.

Authors:  Nalini Vadivelu; Erika Schermer; Gopal Kodumudi; Jack M Berger
Journal:  CNS Drugs       Date:  2016-07       Impact factor: 5.749

Review 6.  Narrative review: buprenorphine for opioid-dependent patients in office practice.

Authors:  Lynn E Sullivan; David A Fiellin
Journal:  Ann Intern Med       Date:  2008-05-06       Impact factor: 25.391

7.  Home buprenorphine/naloxone induction in primary care.

Authors:  Joshua D Lee; Ellie Grossman; Danae DiRocco; Marc N Gourevitch
Journal:  J Gen Intern Med       Date:  2008-12-17       Impact factor: 5.128

Review 8.  Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence.

Authors:  Jennifer S Orman; Gillian M Keating
Journal:  Drugs       Date:  2009       Impact factor: 9.546

9.  Use of an Acetyl Derivative to Improve GC-MS Determination of Norbuprenorphine in the Presence of High Concentrations of Buprenorphine in Urine.

Authors:  Joel R Gervais; Gregory A Hobbs
Journal:  J Anal Toxicol       Date:  2016-01-25       Impact factor: 3.367

10.  A pilot study of a distress tolerance treatment for opiate-dependent patients initiating buprenorphine: rationale, methodology, and outcomes.

Authors:  Richard A Brown; Erika Litvin Bloom; Jacki Hecht; Ethan Moitra; Debra S Herman; Michael D Stein
Journal:  Behav Modif       Date:  2014-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.